Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142436 · ClinicalTrials.gov registry record · NA
BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
A NA study, sponsored by British American Tobacco (Investments) Limited.
- Completed
- Registry status
- NA
- Development phase
- 806
- Enrollment target
NCT05142436: Completed NA study, sponsored by British American Tobacco (Investments) Limited.
NCT05142436 is a NA study that has completed, run by British American Tobacco (Investments) Limited. The registered enrollment target is 806 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05142436, a NA study, has completed, sponsored by British American Tobacco (Investments) Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 806 participants
- Enrollment target
Study Summary
This is a randomized, controlled, multi-center, open-label, 8-cohort parallel group study to assess changes in select biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) in generally healthy smokers switching to the study investigational products (IPs), compared to subjects who continue to smoke, undergo smoking abstinence, or have never smoked.
Primary Outcome
To quantitively assess differences in biomarker of exposure, Total NNAL, at 90 days between subjects who continue to smoke combustible cigarettes (CC) and subjects who switch to an HTP
Interventions
- OTHER Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B
- OTHER Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B
- OTHER Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B
- OTHER Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B
- OTHER Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 806 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2022-12-13 |
| Phase | NA |
What the finished NCT05142436 record still lists
NCT05142436 is an interventional study that assigns participants to a tested intervention. The registered 806 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 5 interventions - of which Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B is the first listed.
NCT05142436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05142436 about?
NCT05142436 is a clinical study titled "BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects". This is a randomized, controlled, multi-center, open-label, 8-cohort parallel group study to assess changes in select biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) in generally healthy smokers switching to the study investigational products (IPs), compared to subjects who cont...
What is the current status of trial NCT05142436?
This trial is currently completed. It is a NA study. The enrollment target is 806 participants. The study started on 2022-01-13. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT05142436?
The interventions under investigation include: Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B (OTHER), Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B (OTHER), Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B (OTHER), Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B (OTHER), Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A (OTHER).
Who is sponsoring clinical trial NCT05142436?
This trial is sponsored by British American Tobacco (Investments) Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05142436's enrollment target sits among peer trials
806 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI